PMID: 9533065Apr 9, 1998Paper

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus

The Annals of Pharmacotherapy
M D JohnsonR K Campbell

Abstract

To introduce troglitazone (CS-045, Rezulin), a new oral antidiabetic agent and discuss its pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy. A MEDLINE database search was completed to identify relevant articles including reviews, recent studies and abstracts, and data from Parke-Davis. Due to the small number of published human studies available, some data are derived from animal studies and abstracts of human studies. Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus. Three of the six published human studies used subjects in a placebo-controlled, multicenter, randomized environment (type 2 diabetic patients or obese subjects with insulin resistance). All clinical trials available, including unpublished reports, were reviewed. Troglitazone is the first member of a new class of medications, the thiazolidinediones, to be approved for clinical use. Troglitazone increases insulin sensitivity in skeletal muscle and in hepatic and adipose tissue. It has been shown to decrease hepatic glucose output while having no effect on stimula...Continue Reading

References

Jan 1, 1976·The American Journal of Medicine·G M ReavenJ M Olefsky
Jan 1, 1990·Diabetic Medicine : a Journal of the British Diabetic Association·L T HoG M Reaven
Oct 1, 1990·Metabolism: Clinical and Experimental·T P CiaraldiK A Heidenreich
Feb 1, 1990·Diabetes/metabolism Reviews·W C KnowlerP H Bennett
Jul 1, 1989·Diabetes Care·M I Harris
Oct 1, 1981·The Journal of Clinical Investigation·O G KoltermanJ M Olefsky
Feb 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A A Lopes, F K Port
Jun 1, 1994·Diabetologia·D I PhillipsC Osmond
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Nov 3, 1994·The New England Journal of Medicine·H Keen
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Apr 1, 1993·Journal of Diabetes and Its Complications·J S Yudkin

❮ Previous
Next ❯

Citations

Mar 29, 2001·Current Hypertension Reports·F RamosR Sánchez
Mar 27, 2002·The Pharmacogenomics Journal·B E Rothberg
Nov 9, 2012·Expert Opinion on Drug Safety·Michele BortoliniBogdana Balas
Dec 29, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Timothy Schulz-UtermoehlIan D Wilson
Oct 30, 1998·The Annals of Pharmacotherapy·C G Fraser, L Fierro
Oct 30, 1998·The Annals of Pharmacotherapy·S G TerraD B May
Jul 10, 2001·The Journal of Clinical Endocrinology and Metabolism·A AljadaP Dandona
Jun 4, 1999·Drug Discovery Today·H Shinkai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.